Shots:
- Angelini Pharma has entered into a definitive agreement to acquire all outstanding shares of Catalyst, marking Angelini’s entry into the US market
- As per the deal, Angelini will acquire Catalyst for $31.5 per share in cash, for a total equity value of ~$4.1B; closing is expected in Q3’26
- The acquisition will strengthen Angelini’s Brain Health & Rare Disease offerings through integration of Catalyst’s portfolio & commercial infrastructure, while expanding its North American presence alongside its core European business
Ref: Globenewswire | Image: Catalyst | Press Release
Related News: Angelini Pharma Enters an Exclusive Option Agreement with Sovargen to Develop and Commercialize SVG105 for Brain Disorders
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
